期刊文献+

间变性少突-星形细胞瘤 被引量:1

Anaplastic Oligoastrocytoma
下载PDF
导出
摘要 间变性少突-星形细胞瘤依据世界卫生组织(WHO)2007病理学分类标准,分级为胶质瘤Ⅲ级。美国NCCN2007指引(Guideline)中,间变性少突-星形细胞瘤的治疗策略是尽最大限度切除肿瘤病灶,术后需要给予放疗和化疗,对于脑室开放者需要全脑放疗。我们收治一例肿瘤位于侧脑室旁的间变性少突-星形细胞瘤患者,该患者系年轻患者,手术时打开了侧脑室,行肿瘤全切除后未予放疗,而是结合肿瘤耐药基因MGMT检测结果(±),给予了12疗程的替莫唑胺化疗,该患者随访至今,无瘤生存已超过2年。本文就此病例的治疗进行讨论。 Anaplastic oligoastrocytoma (AOA) has been classified as glioma WHO grade Ⅲ According to the American NCCN guideline, the patients with AOA should receive total resection followed by the subsequent radiotherapy and chemotherapy. However, the patients should receive the whole brain radiotherapy if tumor invades to the lateral ventricles. We have treated a young female AOA patient with the tumor invaded to right lateral ventricle. The patient whose MGMT expression in the tumor was negative received total resection followed by chemotherapy with temozolomide for 12 cycles, and she received no radiotherapy. The tumor free survival of the patient has amounted to 2 years up to now. This article discussed this special case.
出处 《中国神经肿瘤杂志》 2007年第4期268-272,共5页 Chinese Journal of Neuro-Oncology
关键词 胶质瘤 侧脑室 化疗 glioma lateral ventricle chemotherapy
  • 相关文献

参考文献2

  • 1Athanassios P. Kyritsis,Vinay K. Puduvalli,Victor A. Levin. Chemotherapy as first line treatment for oligodendroglioma[J] 2008,Journal of Neuro - Oncology(3):361~362
  • 2Marie Pierre Sunyach,Anne Jouvet,David Perol,Emmanuel Jouanneau,Jacques Guyotat,Laurence Gignoux,Christian Carrie,Didier Frappaz. Role of exclusive chemotherapy as first line treatment in oligodendroglioma[J] 2007,Journal of Neuro - Oncology(3):319~328

同被引文献11

  • 1Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma[ J]. N Engl J Med, 2005, 352(10) :997 - 1003.
  • 2Ino Y, Betensky RA, Zlatescu MC, et al. Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis[J]. Clin Cancer Res,2001,7(4) :839 -845.
  • 3Chen ZP, Yarosh D, Garcia Y, et al. Relationship between O^6- methylguanine-DNA methyhransferase levels and clinical response induced by chloroethylnitrosourea therapy in glioma patients[ J]. Can J Neurol Sci, 1999, 26(2) : 104 -109.
  • 4Bower M, Newlands ES, Bleehen NM, et al. Muhicentre CRC phase Ⅱ trial of temozolomide in recurrent or progressive high- grade glioma[ J]. Cancer Chemother Pharmacol, 1997, 40 (6) : 484 - 488.
  • 5Sanson M, Ameri A, Monjour A, et al. Treatment of recurrent malignant supratentorial gliomas with ifosfamide, carboplatin and etoposide: a phase Ⅱ study[J]. Eur J Cancer, 1996, 32A(13) : 2229 - 2235.
  • 6Silber JR, Bobola MS, Ghatan S, et al. O^6-methylguanine-DNA methyltransferase activity in adult gliomas: relation to patient and tumor characteristics [ J ]. Cancer Res, 1998,58 (5) : 1068 - 1073.
  • 7Cairncross G, Berkey B, Shaw E, et al. Phase Ⅲ trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402 [ J ]. J Clin Oncol, 2006,24 (18) :2707 -2714.
  • 8Van den Bent M J, Carpentier AF, Brandes AA, et al. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase Ⅲ trial [J]. J Clin Oncol, 2006, 24(18) :2715 -2722.
  • 9杨学军,江涛,陈忠平,漆松涛.脑胶质瘤的规范化和个体化治疗与临床实践[J].中国神经精神疾病杂志,2009,35(6):321-322. 被引量:9
  • 10王增光,杨学军,潘强,高松,杨树源.MGMT在恶性胶质瘤中的表达对替莫唑胺化疗预后的影响[J].中国神经精神疾病杂志,2009,35(6):327-330. 被引量:6

引证文献1

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部